CSOP Yinhua CSI 5G Communications Theme ETF (03193.HK) Rises 4.87% to HK$20.460
NewTimeSpace News, as of 14:30 on May 26, the CSOP Yinhua CSI 5G Communications Theme ETF (03193.HK) gained 4.87%, trading at HK$20.460. The intraday high was HK$20.460 and the low was HK$20.080, with an average price of HK$20.304. The latest Net Asset Value (NAV) per unit is HK$19.568, representing a discount of -0.30%. The total AUM is approximately HK$15.686 million.
The CSOP Yinhua CSI 5G Communications Theme ETF (03193.HK) tracks the CSI 5G Communication Index, a representative benchmark specifically designed to track the performance of the entire 5G industry chain within the A-share market. Its constituent stocks cover high-quality leading enterprises ranging from upstream planning and design to midstream core equipment (such as optical modules and base station components) and downstream application scenarios.
Centering on the Telecommunications, Electronics, and Computer sectors, the index possesses significant "hard tech" attributes and high-growth characteristics. It serves as an essential tool-based investment vehicle for investors seeking to allocate to core "New Infrastructure" assets and capture the dividends of telecommunication technology iterations.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Daily Report on Hong Kong-Listed LLM Concept Stocks (July 10, 2026)
- KNOWLEDGE ATLAS(02513.HK) closed 19.29% lower, closing at HKD 1640
- TAN CHONG INT'L (00693.HK): Expected Unrealised Investment Loss of HK$512 Million for First Half Due to Share Price Movements of Listed Investments
- SBP GROUP (01177.HK): NDA Accepted for Category 1 Innovative Drug IDH1 Inhibitor TQB3454 for Advanced Biliary Tract Cancer
- Pizu Group(09893.HK): Change of Independent Non-executive Director, Appointment of Wei Lai